{"groups":[{"description":"cabozantinib (60 mg) once daily orally (qd)\n\nCabozantinib: Tablets containing 60-mg or 20-mg cabozantinib once daily orally.","id":"FG000","title":"Cabozantinib"},{"description":"placebo once daily orally (qd)\n\nPlacebo: Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"29"}],"type":"Radiographic Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"6"}],"type":"Clinical deterioration"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"125"},{"groupId":"FG001","numSubjects":"62"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"89"},{"groupId":"FG001","numSubjects":"26"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"36"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}